Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI vs TIO/OLO in Moderate COPD
NCT02799784Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of Anoro Ellipta in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Trough Forced Expiratory Volume in One Second at Week 8. Started Jul 2016; status: completed.
02
Drugs
Anoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02799784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799784.